Literature DB >> 1531631

Random mutagenesis of CSF-1 receptor (FMS) reveals multiple sites for activating mutations within the extracellular domain.

T van Daalen Wetters1, S A Hawkins, M F Roussel, C J Sherr.   

Abstract

Retroviral vectors containing human FMS protooncogene cDNA were reconfigured to allow single-step excision and reinsertion of restriction fragments encoding short segments of the extracellular domain of the colony-stimulating factor 1 receptor (CSF-1R). Fragments ligated into M13 bacteriophages were subjected to random chemical mutagenesis on both strands and recloned into the parental vector to create libraries of FMS genes containing mutations restricted to predefined target cassettes. Transfection of retroviral vector libraries into NIH/3T3 cells gave rise to transformed foci from which cellular DNA was amplified by the polymerase chain reaction (PCR), using primers flanking the mutagenized target sequences. Amplified fragments from individual primary transformants were recloned into intact FMS vector plasmids, and those with transforming activity were subjected to nucleotide sequence analysis. Alternatively, retroviruses rescued from transformed cells by superinfection with helper virus were used to generate secondary transformants containing unique copies of proviral DNA, whose sequences were determined after PCR amplification. Novel activating mutations were identified within sequences separating the third and fourth immunoglobulin-like loops, as well as within non-covalently stabilized loop 4 of the CSF-1R extracellular domain. Thus, FMS mutations able to convert human CSF-1R to an active oncoprotein are not restricted to those previously identified at codon 301. This approach should be generally applicable for defining activating mutations in related growth factor receptors, including those for platelet-derived growth factor and Steel factor (KIT ligand), in which ligand-independent oncoprotein variants have not been identified.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1531631      PMCID: PMC556486          DOI: 10.1002/j.1460-2075.1992.tb05086.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  27 in total

1.  A general method for saturation mutagenesis of cloned DNA fragments.

Authors:  R M Myers; L S Lerman; T Maniatis
Journal:  Science       Date:  1985-07-19       Impact factor: 47.728

2.  Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors.

Authors:  Y Yarden; J A Escobedo; W J Kuang; T L Yang-Feng; T O Daniel; P M Tremble; E Y Chen; M E Ando; R N Harkins; U Francke
Journal:  Nature       Date:  1986 Sep 18-24       Impact factor: 49.962

3.  "Replacement" of COOH-terminal truncation of v-fms with c-fms sequences markedly reduces transformation potential.

Authors:  P J Browning; H F Bunn; A Cline; M Shuman; A W Nienhuis
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

4.  The gapped duplex DNA approach to oligonucleotide-directed mutation construction.

Authors:  W Kramer; V Drutsa; H W Jansen; B Kramer; M Pflugfelder; H J Fritz
Journal:  Nucleic Acids Res       Date:  1984-12-21       Impact factor: 16.971

5.  Construction and applications of a highly transmissible murine retrovirus shuttle vector.

Authors:  C L Cepko; B E Roberts; R C Mulligan
Journal:  Cell       Date:  1984-07       Impact factor: 41.582

6.  Monoclonal antibodies to the transformation-specific glycoprotein encoded by the feline retroviral oncogene v-fms.

Authors:  S J Anderson; M Furth; L Wolff; S K Ruscetti; C J Sherr
Journal:  J Virol       Date:  1982-11       Impact factor: 5.103

7.  CSF-1--a mononuclear phagocyte lineage-specific hemopoietic growth factor.

Authors:  E R Stanley; L J Guilbert; R J Tushinski; S H Bartelmez
Journal:  J Cell Biochem       Date:  1983       Impact factor: 4.429

8.  Transforming activities of human CSF-1 receptors with different point mutations at codon 301 in their extracellular domains.

Authors:  M F Roussel; J R Downing; C J Sherr
Journal:  Oncogene       Date:  1990-01       Impact factor: 9.867

9.  Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia.

Authors:  K Tobal; A Pagliuca; B Bhatt; N Bailey; D M Layton; G J Mufti
Journal:  Leukemia       Date:  1990-07       Impact factor: 11.528

10.  Genomes of murine leukemia viruses isolated from wild mice.

Authors:  S K Chattopadhyay; A I Oliff; D L Linemeyer; M R Lander; D R Lowy
Journal:  J Virol       Date:  1981-09       Impact factor: 5.103

View more
  3 in total

1.  TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor.

Authors:  J C Arevalo; B Conde; B L Hempstead; M V Chao; D Martin-Zanca; P Perez
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

Review 2.  Tyrosine kinase inhibitors in preclinical development.

Authors:  M L Levitt; P P Koty
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

3.  The effect of activating mutations on dimerization, tyrosine phosphorylation and internalization of the macrophage colony stimulating factor receptor.

Authors:  K Carlberg; L Rohrschneider
Journal:  Mol Biol Cell       Date:  1994-01       Impact factor: 4.138

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.